Myles HelfandExecutive Editor
Myles is the executive editor and general manager of TheBody/TheBodyPro. A career journalist and editor, Myles joined TheBody in 2001 as a part-time copyeditor. He has since established himself as a leading journalist and content strategist on HIV-related issues, authoring hundreds of articles and editing hundreds more -- and accumulating an ever-growing mountain of HIV conference badges along the way.
Latest by Myles Helfand
May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.
Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.
May 14, 2020: Recurring low-level viremia and morbidity/mortality risk; factors affecting severe bacterial infection in people with HIV; infective endocarditis cases on the rise; high rates of opioid use among U.S. veterans with HIV.
May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.
April 30, 2020: Substance use relapse following opioid therapy for chronic pain; affect of cannabis on blood-brain barrier disruptions; PrEP considerations for adolescents; updated CDC contraceptive recommendations for women at risk for HIV.
The latest update to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of people living with HIV occurred within the pediatric treatment guidelines on April 14.
April 23, 2020: The corps of front-line care providers with HIV-specific experience is aging and retiring, leaving behind a growing need for quality care. We examine recent research and analysis that both describes that need and offers interventions to meet it.
April 16, 2020: Anticoagulants and antiretroviral boosters; durvalumab doesn't impair antiretroviral therapy; cigarette use and oral HPV incidence; using common labs to predict Kaposi sarcoma risk.
April 9, 2020: Rapid efficacy of integrase-based treatment; a potent PrEP ad campaign in Chicago; more frequent STI screening for PrEP users; Ryan White funding fuels critical rural HIV care and services.
April 2, 2020: Physical activity vs. heart med adherence; reducing the burden of HIV emergency care; increasing smoking cessation intervention success; virologic failure following asymptomatic HIV treatment initiation.